PODD: Ascending Triangle detected on 30 Jul 2026

PODD is forming an ascending triangle with excellent structure quality (15.0/15) at the tight confluence of support and resistance. The stock trades at $170.62, hovering just below key resistance at $170.83, with strong support at $163.24—a 4.5% cushion below current price. The breakout score of 12.5/13 and volume score of 10.0/12 indicate solid but not exceptional confirmation; recent volume at 1.1M shares trades 13% below the 20-day average, signaling caution. The overall pattern scores 80.5/98 with a 62% win probability. Positive momentum is evident: RSI at 62 (approaching overbought without excess), MACD histogram positive at 0.601, and the stock has gained 7.4% in one week and 8.2% over one month despite being down 6.7% over three months.

Insulet is set to report Q2 2026 earnings on August 5, with analysts expecting adjusted EPS of $1.38, an 18% increase from the previous year. However, significant headwinds are present. On May 26, 2026, Insulet disclosed a voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System Pods due to a manufacturing issue that could result in insulin under-delivery, causing the stock to decline approximately 5% that day. The May correction affected approximately 7 million pods, representing 8.5% of 2025 global production. Multiple shareholder securities fraud lawsuits have been filed alleging the company made materially false and misleading statements regarding its business operations, growth prospects, and financial stability. On July 29, 2026, UBS downgraded Insulet from Buy to Neutral. The ascending triangle is forming in the recovery phase after these manufacturing scandals, but litigation risk remains elevated with August 31, 2026 deadline for lead plaintiff appointment in class actions.

A successful breakout above the $170.83 resistance level would target the conservative measured move at $177.50, representing a 4% upside from current price. Volume confirmation is critical—the ascending triangle must break on above-average volume (>1.3M shares) to validate the move; current volume of 0.87 ratio suggests institutional participation remains hesitant. The invalidation level sits at key support of $163.24; a breakdown below this level would negate the pattern and suggest resumption of the broader downtrend from $236 highs. The 62% win probability reflects moderate confidence—this is a decent setup but not a high-confidence breakout scenario. The health care sector is in a bullish regime (+0.92 score), providing tailwind, though the broader market remains in a bearish regime (-0.24).

Q2 earnings release on August 5 could catalyze sharp volatility as the market recalibrates expectations around manufacturing quality and margins. Litigation risk is acute: multiple class action lawsuits allege significant disclosure failures regarding manufacturing defects, with the lead plaintiff deadline on August 31, 2026. The prior stock collapse from $236 to $146 demonstrates investor skepticism about management credibility remains high. Low volume (0.87 relative volume) and below-average shares traded suggest institutional buyers are not yet committed to the recovery narrative. Beta of -0.31 is unusually negative, indicating PODD may not participate in broader market rallies—bearish market regime (-0.24) could further pressure breakout momentum. ATR at 3.65% implies volatility elevated relative to structure; a gap or adverse earnings surprise could trigger rapid unwinds through support.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.